Parkinson’s disease is a chronic, progressive, neurodegenerative disorder affecting one million people in the United States and seven million worldwide. Disease symptoms can be ameliorated by the drug L-DOPA; however, its chronic use eventually leads to the majority of patients developing involuntary movements known as L-Dopa Induced Dyskinesia (LID), which itself can be disabling. Currently, the medical management of these complications is a major unmet need for this patient population.

MentiNova’s primary strategy is to use a drug that is currently clinically approved for another indication and repurpose it for the treatment of L-Dopa Induced Dyskinesia in patients with Parkinson’s disease. This path can provide a critically needed medication in a rapid timeframe. MentiNova is aggressively pursuing development with comprehensive scientific, clinical and business considerations to expeditiously provide benefit to patients.